Literature DB >> 17273168

Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Jane A Leopold1, Aamir Dam, Bradley A Maron, Anne W Scribner, Ronglih Liao, Diane E Handy, Robert C Stanton, Bertram Pitt, Joseph Loscalzo.   

Abstract

Hyperaldosteronism is associated with impaired vascular reactivity; however, the mechanisms by which aldosterone promotes endothelial dysfunction remain unknown. Glucose-6-phosphate dehydrogenase (G6PD) modulates vascular function by limiting oxidant stress to preserve bioavailable nitric oxide (NO(*)). Here we show that aldosterone (10(-9)-;10(-7) mol/l) decreased endothelial G6PD expression and activity in vitro, resulting in increased oxidant stress and decreased NO(*) levels-similar to what is observed in G6PD-deficient endothelial cells. Aldosterone decreased G6PD expression by increasing expression of the cyclic AMP-response element modulator (CREM) to inhibit cyclic AMP-response element binding protein (CREB)-mediated G6PD transcription. In vivo, infusion of aldosterone decreased vascular G6PD expression and impaired vascular reactivity. These effects were abrogated by spironolactone or vascular gene transfer of G6pd. These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17273168      PMCID: PMC3648863          DOI: 10.1038/nm1545

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  47 in total

Review 1.  Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone.

Authors:  Karl T Weber
Journal:  J Lab Clin Med       Date:  2003-08

2.  Inhibitors of the catalytic activity of bovine adrenal glucose-6-phosphate dehydrogenase.

Authors:  W E Criss; K W McKerns
Journal:  Biochim Biophys Acta       Date:  1969-09-02

3.  Effects of aldosterone on blood pressure and glucose-6-phosphate dehydrogenase activity of heart muscle.

Authors:  C C Liew; A G Gornall
Journal:  Can J Physiol Pharmacol       Date:  1969-02       Impact factor: 2.273

4.  Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway.

Authors:  Frédéric Michel; Marie-Lory Ambroisine; Micheline Duriez; Claude Delcayre; Bernard I Levy; Jean-Sébastien Silvestre
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

5.  Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy.

Authors:  Ademola K Abiose; George A Mansoor; MaryBeth Barry; Richard Soucier; Chandra K Nair; David Hager
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

Review 6.  Aldosterone-induced vasculopathy.

Authors:  Allan D Struthers
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

7.  Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.

Authors:  J E Macdonald; N Kennedy; A D Struthers
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

8.  Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism.

Authors:  Mari K Nishizaka; M Amin Zaman; Sharon A Green; Kerry Y Renfroe; David A Calhoun
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

9.  Cyclic AMP-mediated upregulation of the expression of neuronal NO synthase in human A673 neuroepithelioma cells results in a decrease in the level of bioactive NO production: analysis of the signaling mechanisms that are involved.

Authors:  Jean-Paul Boissel; Matthias Bros; Andreas Schröck; Ute Gödtel-Armbrust; Ulrich Förstermann
Journal:  Biochemistry       Date:  2004-06-08       Impact factor: 3.162

10.  Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice.

Authors:  Anne Garnier; Jennifer K Bendall; Sebastien Fuchs; Brigitte Escoubet; Francesca Rochais; Jacqueline Hoerter; Johnny Nehme; Marie-Lory Ambroisine; Noeleen De Angelis; Gilles Morineau; Pauline d'Estienne; Rodolphe Fischmeister; Christophe Heymes; Florence Pinet; Claude Delcayre
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

View more
  125 in total

1.  Reciprocal regulation of 11β-hydroxysteroid dehydrogenase 1 and glucocorticoid receptor expression by dexamethasone inhibits human coronary artery smooth muscle cell proliferation in vitro.

Authors:  George Michas; Marcel Liberman; Kristian C Becker; Diane E Handy; Joseph Loscalzo; Jane A Leopold
Journal:  Mol Cell Biochem       Date:  2010-10-05       Impact factor: 3.396

2.  A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.

Authors:  Wenfeng Tan; Hui Wu; Jian Zhao; Lezlie A Derber; David M Lee; Nancy A Shadick; Doyt L Conn; Edwin A Smith; Vivian H Gersuk; Gerald T Nepom; Larry W Moreland; Daniel E Furst; Susan D Thompson; Beth L Jonas; V Michael Holers; David N Glass; Pojen P Chen; S Louis Bridges; Michael E Weinblatt; Harold E Paulus; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2010-10

3.  Use of medications to lower urine protein level in patients with diabetic kidney disease.

Authors:  Robert C Stanton
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 4.  Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.

Authors:  Mindy Markowitz; Frank Messineo; Neil L Coplan
Journal:  Clin Cardiol       Date:  2012-07-06       Impact factor: 2.882

Review 5.  S-nitrosothiols and the S-nitrosoproteome of the cardiovascular system.

Authors:  Bradley A Maron; Shiow-Shih Tang; Joseph Loscalzo
Journal:  Antioxid Redox Signal       Date:  2012-09-05       Impact factor: 8.401

6.  Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action.

Authors:  Patricia Coutinho; Christopher Vega; Luminita H Pojoga; Alicia Rivera; Gregory N Prado; Tham M Yao; Gail Adler; Manuel Torres-Grajales; Enrique R Maldonado; Arelys Ramos-Rivera; Jonathan S Williams; Gordon Williams; Jose R Romero
Journal:  Endocrinology       Date:  2014-03-21       Impact factor: 4.736

7.  Aldosterone receptor antagonists: effective but often forgotten.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 8.  The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction.

Authors:  Fei Wu; Yun Lin; Qingyong Liu
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

9.  Hypoxia-induced glucose-6-phosphate dehydrogenase overexpression and -activation in pulmonary artery smooth muscle cells: implication in pulmonary hypertension.

Authors:  Sukrutha Chettimada; Rakhee Gupte; Dhwajbahadur Rawat; Sarah A Gebb; Ivan F McMurtry; Sachin A Gupte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-05       Impact factor: 5.464

10.  Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells.

Authors:  Bradley A Maron; Ying-Yi Zhang; Diane E Handy; Annie Beuve; Shiow-Shih Tang; Joseph Loscalzo; Jane A Leopold
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.